Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript
Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.2.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,453,405 | $16,069,803 | +7% | 0.96% |
2. | 683 Capital Partners Ari Zweiman | 540,800 | $3,542,240 | 0.29% | |
3. | Citadel Investment Group Ken Griffin | 334,777 | $2,192,789 | +100% | 0% |
4. | Armistice Capital Steven Boyd | 268,000 | $1,755,400 | 0.02% | |
5. | 85,165 | $557,831 | +29% | 0% |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$5.13 | 500 | Officer | 3,500 | 2023-09-05 | Filing | |
$4.96 | 1,000 | Officer | 15,309 | 2023-09-06 | Filing | |
$5.13 | 10,000 | Director | 20,000 | 2023-09-05 | Filing | |
$4.88 | 10,000 | Director | 10,000 | 2023-09-06 | Filing | |
$5.42 | 1,000 | Officer | 3,000 | 2023-05-19 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 2,410,289 | $15,787,393 | 0% | |
2. | 1,645,140 | $10,775,667 | 0% | |
3. | 729,179 | $4,776,597 | 0% | |
4. | 636,060 | $4,166,193 | 0% | |
5. | 387,427 | $2,537,647 | 1.14% |